Sertraline usage

Standard antidepressant may be ineffective with chronic kidney disease patients

A clinical trial involving hundreds of participants has shown that one of the most frequently prescribed antidepressants may not benefit millions of patients who also have chronic kidney disease (CKD).

Photo
Dr. Susan Hedayati and Dr. Madhukar Trivedi.
Source: UT Southwestern Medical Center

“These results provide evidence that could change clinical practice,” said Dr. Susan Hedayati, Professor of Internal Medicine at UT Southwestern and first author of the study, which was published online in JAMA. “The findings do not support the use of sertraline to treat major depression in patients with nondialysis CKD stage 3, 4, or 5,” added Dr. Hedayati, the Department of Internal Medicine’s Associate Vice Chair for Research. “Importantly, sertraline resulted in a significantly higher incidence of adverse side effects such as nausea and vomiting.”

Sertraline is a selective serotonin reuptake inhibitor, or SSRI. Patients with advanced CKD are at significantly increased risk for developing depression and as well as serious complications of kidney disease, she added. The CAST (Chronic Kidney Disease Antidepressant Sertraline Trial) investigation, based at UT Southwestern and two other Dallas healthcare institutions, involved 201 participants with nondialysis-dependent CKD.

According to the United States Renal Data System, CKD affected 15 percent – 48,405,000 – of the 322.7 million people in the U.S. in 2016, the latest reported year. Up to 25 percent of CKD patients also suffer from depression, and many of these depressed patients routinely received SSRI therapy. The incidence of depression in this patient group is four times that of the general public. “Our research previously reported in JAMA showed that major depression is associated with a significantly higher risk of death, dialysis initiation, and hospitalization among patients with CKD,” said Dr. Hedayati, holder of the Yin Quan-Yuen Distinguished Professorship and a faculty member in the Division of Nephrology at UT Southwestern. “There is an urgent need for researchers to investigate the unique biological mechanisms of this subtype of depression and to develop novel treatment strategies.”

These findings also suggest an urgent need for us to understand the unique pathology associated with depression among patients with chronic kidney disease

Madhukar Trivedi

The research team’s 2010 investigation showed that depressed CKD patients were almost twice as likely to die, become hospitalized, or begin dialysis within a year than those without depression. This association was independent of the severity of kidney disease and other medical illnesses, such as diabetes. “Depression is a complex disorder with varied causes. These latest results strongly suggest a subtype that does not respond to commonly prescribed medications and may require alternative treatments like exercise, transcranial magnetic stimulation, psychotherapy or truly novel medications that require further study,” said Dr. Madhukar Trivedi, Professor of Psychiatry and senior author of the CAST study. “These findings also suggest an urgent need for us to understand the unique pathology associated with depression among patients with chronic kidney disease.”

Dr. Hedayati said it is too early to apply the study’s findings universally to CKD patients: “We advise caution in extrapolating these results to patients with very early stages of CKD, because about 90 percent of the study participants had moderate to severe nondialysis CKD.”

Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and the Department of Veterans Affairs, the current study, which took place over a six-year period is a randomized, double-blinded, placebo-controlled trial undertaken at UT Southwestern, Parkland Hospital, and the VA North Texas Health Care System.


Source: UT Southwestern Medical Center

05.11.2017

Read all latest stories

Related articles

Photo

Mineral menace

Multiple Sclerosis: Do zinc and iron play a role?

Some studies have suggested that minerals such as zinc and iron may play a role in how multiple sclerosis (MS) progresses, once people have been diagnosed with it. But little was known about whether…

Photo

Oral contraceptives

Can birth control pills keep you from recognising emotions?

The pill could be blurring your social judgement ‒ but perhaps not enough so you'd notice. By challenging women to identify complex emotional expressions like pride or contempt, rather than basic…

Photo

Multiple sclerosis

Old cells repair damage in the brains of MS patients

A new study shows that there is a very limited regeneration of cells in the brain of patients diagnosed with multiple sclerosis (MS). These findings underline the importance of treating MS at an…

Related products

Eppendorf – Mastercycler nexus X2

Research Use Only (RUO)

Eppendorf – Mastercycler nexus X2

Eppendorf AG
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only (RUO)

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030

Research Use Only (RUO)

Shimadzu – CLAM-2030

Shimadzu Europa GmbH